Pacira Pharmaceuticals (PCRX) AI Stock Analysis

• Market Cap: $1.13B
• Dividend Yield: N/A
• Average Volume (3M): 662.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: 2.25%
• EPS Growth: -301.59%
• Country: US
• Employees: 788
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.74
• Shares Outstanding: 44,932,720
• 10 Day Avg. Volume: 931,943
• 30 Day Avg. Volume: 662,033
• PEG Ratio: 0.03
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 1.24
• P/FCF Ratio: 4.87
• Enterprise Value/Market Cap: 1.12
• Enterprise Value/Revenue: 1.80
• Enterprise Value/Gross Profit: 3.09
• Enterprise Value/Ebitda: -60.01
• 1Y Price Target: $28.67
• Price Target Upside: 13.86% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 5

• Rating: 59 Neutral
• Price Target: $23.50 ▼(-6.67% Downside)

Pacira Pharmaceuticals' overall stock score is primarily influenced by its strong earnings call performance, which highlights strategic partnerships and improved financial metrics. However, the company's financial performance is hindered by high leverage and negative profitability, and the technical analysis suggests a lack of strong momentum. The valuation is also a concern due to the negative P/E ratio and absence of a dividend yield.

Positive Factors

Patent Settlement

The settlement with Fresenius Kabi and Jiangsu Hengrui is seen as favorable for Pacira, representing profound upside to the current valuation.

Share Repurchase Program

A new $300MM share repurchase program has been announced.

Strategic Partnerships

A new co-promote partnership with J&J MedTech for Zilretta is anticipated to boost sales.

Negative Factors

Competitive Pressures

There are concerns about competitive pressures impacting Pacira's market share.

Regulatory Challenges

Regulatory challenges could pose risks to Pacira's upcoming product launches.

Revenue Performance

Exparel sales missed expectations for the second straight quarter.

Pacira Pharmaceuticals Business Overview & Revenue Model

Company Description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

How the Company Makes Money

Pacira Pharmaceuticals generates revenue primarily through the sale of its core product, EXPAREL, which is widely used in hospitals and surgical centers to manage post-surgical pain. The company's revenue model is centered on the distribution and commercialization of EXPAREL, which is marketed directly to healthcare providers. Additionally, Pacira may generate income through partnerships and collaborations with other pharmaceutical companies, aimed at expanding the application of their products and enhancing market penetration. The company's earnings are significantly influenced by factors such as regulatory approvals, market adoption of non-opioid pain management solutions, and ongoing clinical research to support the efficacy and safety of its products.

Pacira Pharmaceuticals Financial Statement Overview

Summary

Pacira Pharmaceuticals shows stable revenue growth and strong gross margins, but faces challenges with profitability and high leverage. While cash flow generation is strong, supporting operational liquidity, the high debt levels and negative net income weigh down the financial outlook.

Income Statement

Pacira Pharmaceuticals shows a modest revenue growth in the TTM with a 0.26% increase from the previous year. However, profitability metrics are concerning, with negative EBIT and net profit margins, indicating operational challenges. The gross profit margin remains healthy at approximately 73.6%, suggesting strong core business profitability despite overall losses.

Balance Sheet

The company's balance sheet reflects a somewhat stable position with an equity ratio of 50.3%, indicating moderate reliance on debt. However, the debt-to-equity ratio is high at 0.8, suggesting potential risk from leverage. Despite these challenges, the return on equity is negative, impacted by the net loss, which is a concern for future profitability.

Cash Flow

Operating cash flow remains robust, with an operating cash flow to net income ratio of -1.69, indicating strong cash generation relative to accounting losses. The free cash flow growth rate is negative year-over-year, but the company still maintains a positive free cash flow, which is a positive sign for liquidity management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	705.85M	700.97M	674.98M	666.82M	541.53M	420.83M
Gross Profit	411.69M	530.54M	490.31M	467.53M	401.28M	303.50M
EBITDA	-21.20M	29.12M	157.58M	144.78M	118.47M	71.42M
Net Income	-127.46M	-99.56M	41.95M	15.91M	41.98M	145.52M
Balance Sheet
Total Assets	1.54B	1.55B	1.57B	1.68B	2.08B	1.27B
Cash, Cash Equivalents and Short-Term Investments	300.48M	484.62M	278.58M	288.65M	656.41M	521.66M
Total Debt	492.28M	638.85M	586.04M	763.39M	1.13B	541.13M
Total Liabilities	779.50M	775.17M	704.26M	906.19M	1.34B	654.83M
Stockholders Equity	757.77M	778.35M	870.13M	775.01M	730.41M	619.69M
Cash Flow
Free Cash Flow	117.07M	178.75M	139.49M	115.20M	79.85M	39.23M
Operating Cash Flow	134.52M	189.39M	154.65M	145.27M	125.72M	77.03M
Investing Cash Flow	-16.00M	-83.28M	77.54M	-225.19M	-20.79M	-277.61M
Financing Cash Flow	-65.30M	17.36M	-183.03M	-401.53M	380.69M	222.30M

Pacira Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCRX, the sentiment is Positive. The current price of 25.18 is above the 20-day moving average (MA) of 22.46, above the 50-day MA of 23.68, and above the 200-day MA of 22.66, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 65.04 is Neutral, neither overbought nor oversold. The STOCH value of 78.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PCRX.

Pacira Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COLL	75 Outperform	$1.10B	33.72	16.16%	―	22.61%	-63.00%
AMPH	74 Outperform	$1.11B	8.91	18.32%	―	1.37%	-18.10%
ANIP	73 Outperform	$1.77B	―	-2.82%	―	38.68%	-160.14%
SUPN	65 Neutral	$2.31B	36.03	6.38%	―	5.55%	1145.24%
AVDL	60 Neutral	$1.24B	―	-3.63%	―	132.35%	97.34%
PCRX	59 Neutral	$1.13B	―	-15.57%	―	2.25%	-301.59%
Sector *	51 Neutral	$7.78B	-0.48	-63.43%	2.34%	17.02%	-4.15%

Pacira Pharmaceuticals Corporate Events

Pacira Pharmaceuticals Implements Workforce Reduction for Efficiency

On July 9, 2025, Pacira BioSciences, Inc. implemented a workforce reduction at its San Diego Science Center Campus due to improved manufacturing efficiencies for EXPAREL, resulting from investments in large-scale manufacturing suites. This decision led to the decommissioning of a 45-liter manufacturing suite and affected 71 employees, approximately 8% of the workforce. The company anticipates recognizing pre-tax charges of $2.4 million to $2.8 million related to employee termination benefits and expects an annual reduction in operating expenses of approximately $13 million. The move reflects Pacira’s strategic focus on optimizing production capacity and cost structure to support growing demand for its products.

The most recent analyst rating on (PCRX) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.

Pacira Pharmaceuticals Secures New $300M Credit Facility

On July 3, 2025, Pacira BioSciences, Inc. entered into a new credit agreement with Wells Fargo Bank and other lenders to refinance its existing credit agreement and provide ongoing working capital. The agreement includes a $300 million senior secured revolving credit facility, with a maturity date of July 3, 2030, and is secured by the company’s and its subsidiaries’ assets. The company used part of this facility to repay its previous credit agreement without incurring prepayment penalties, potentially enhancing its financial flexibility and operational capacity.

The most recent analyst rating on (PCRX) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.

Pacira Pharmaceuticals Stockholders Approve Amended Incentive Plan

On June 10, 2025, Pacira BioSciences, Inc. held its Annual Meeting of Stockholders in Parsippany, New Jersey, where stockholders approved the Amended and Restated 2011 Stock Incentive Plan, increasing the number of shares authorized for grant by 2,500,000. Additionally, the meeting included the election of directors, ratification of KPMG LLP as the accounting firm, and decisions on executive compensation, with the board opting for annual advisory votes on executive pay, reflecting a commitment to good corporate governance.

The most recent analyst rating on (PCRX) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Pacira Pharmaceuticals stock, see the PCRX Stock Forecast page.